Raymond James Financial Inc. Makes New $2.33 Million Investment in Xencor, Inc. (NASDAQ:XNCR)

Raymond James Financial Inc. purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 101,346 shares of the biopharmaceutical company's stock, valued at approximately $2,329,000. Raymond James Financial Inc. owned approximately 0.14% of Xencor as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in XNCR. GAMMA Investing LLC raised its holdings in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 508 shares during the last quarter. KBC Group NV grew its stake in shares of Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 813 shares during the period. PNC Financial Services Group Inc. increased its holdings in Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock valued at $93,000 after buying an additional 1,337 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Xencor during the 4th quarter valued at $239,000. Finally, Mutual of America Capital Management LLC purchased a new stake in shares of Xencor in the 4th quarter worth $244,000.

Analyst Ratings Changes

Several research firms have recently commented on XNCR. StockNews.com downgraded Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company decreased their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. William Blair began coverage on shares of Xencor in a research report on Monday, April 21st. They issued an "outperform" rating for the company. Finally, Wedbush restated an "outperform" rating and set a $31.00 price objective on shares of Xencor in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $32.86.

Xencor Price Performance

Shares of XNCR stock traded down $0.66 during trading hours on Monday, hitting $10.60. The stock had a trading volume of 69,044 shares, compared to its average volume of 619,284. The stock's 50-day moving average price is $11.31 and its two-hundred day moving average price is $18.04. Xencor, Inc. has a one year low of $7.16 and a one year high of $27.24. The stock has a market capitalization of $754.00 million, a price-to-earnings ratio of -3.32 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $52.79 million for the quarter, compared to analysts' expectations of $17.14 million. Equities analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.